Loading
LOADING
Three peptides from a research field that did not exist 25 years ago — mitochondrial-derived peptides, their roles in aging biology, and what early clinical translation looks like.
For most of biology's history, the genetic code in mitochondria was thought to encode only the 13 proteins involved in the electron transport chain — the cellular machinery that produces ATP. This view changed in 2003 when researchers identified a small peptide produced from the mitochondrial 16S ribosomal RNA gene. The peptide was named Humanin for its initially documented neuroprotective effects.
Subsequent research has identified additional mitochondrial-derived peptides, including MOTS-c (Mitochondrial Open Reading frame of the Twelve S rRNA type-c) and the SHLP family (Small Humanin-Like Peptides). These compounds represent a genuinely new class — peptides encoded within the mitochondrial genome that exert effects far beyond the mitochondrion itself, including roles in cellular signaling, metabolism, neuroprotection, and apoptosis regulation.
Separately, synthetic peptides have been developed to target mitochondrial function from the outside. Elamipretide (also called SS-31, Bendavia, or MTP-131) is a synthetic tetrapeptide designed to accumulate in mitochondrial membranes and stabilize cardiolipin, with documented effects on mitochondrial function.
These three compounds — MOTS-c, Humanin, and Elamipretide — represent the most extensively researched members of the broader mitochondrial peptide landscape.
Humanin is a 24-amino-acid peptide produced from the mitochondrial 16S rRNA gene. Despite its mitochondrial origin, Humanin is secreted from cells and acts as an extracellular signaling molecule.
A 2010 review in Molecular Neurobiology examined Humanin biology and the receptors mediating its effects. The compound appears to act through multiple receptor systems:
The breadth of receptor interactions suggests Humanin's effects depend on context — different cellular environments engage different receptor systems and produce different downstream effects.
The original observations driving Humanin's discovery involved neuroprotection — specifically, protection against amyloid-beta-induced neuronal death in models relevant to Alzheimer's disease. The mechanism involves inhibition of the apoptotic cascade through interactions with Bcl-2 family proteins.
A 2021 study in Life Sciences examined Humanin as a mitochondrial-derived peptide in the treatment of apoptosis-related disorders, summarizing the breadth of conditions where Humanin's anti-apoptotic activity has shown effects in preclinical models.
A 2023 review in Biology specifically examined the neuroprotective action of Humanin and Humanin analogues, focusing on neurological applications.
A 2020 study in Aging documented that Humanin is a regulator of lifespan and healthspan in animal models. The compound's expression decreases with age, and supplementation can extend life and health markers in laboratory models.
A 2014 study in Aging Cell documented that IGF-I regulates the age-dependent signaling peptide Humanin, demonstrating cross-talk between the IGF-1 axis and Humanin biology — a connection mechanistically interesting given both pathways' independent roles in aging biology.
A 2024 study in Cell Death and Disease examined Humanin's role in glioblastoma, documenting that Humanin can activate the integrin αV-TGFβ axis and contribute to glioblastoma progression in some contexts.
This finding illustrates an important caveat for peptide research generally: a compound that protects normal cells from apoptosis may also protect cancer cells from apoptosis. The anti-apoptotic activity that makes Humanin promising for neurodegenerative disease research may be problematic in cancer biology.
MOTS-c is a 16-amino-acid peptide derived from the mitochondrial 12S rRNA gene, identified in 2015. A foundational 2015 study in Cell Metabolism characterized MOTS-c as a regulator of metabolic homeostasis, with documented effects on:
A 2021 study in the American Journal of Physiology specifically documented that MOTS-c reduces myostatin and muscle atrophy signaling. This finding generated research interest in MOTS-c for muscle health applications, particularly in aging populations where sarcopenia is a major clinical concern.
A 2025 pilot study in Medicina examined MOTS-c levels in relation to sarcopenia risk in chronic peritoneal dialysis patients, providing early clinical correlation data.
A 2022 review in the International Journal of Molecular Sciences examined MOTS-c as the most recent mitochondrial-derived peptide in human aging and age-related diseases. The peptide's effects on metabolism, muscle, and cellular homeostasis position it as a candidate for aging-related research applications.
A 2023 review in Frontiers in Endocrinology specifically examined MOTS-c for therapeutic exploitation, summarizing the development trajectory of the compound and the range of potential applications.
Elamipretide is mechanistically distinct from Humanin and MOTS-c. Rather than being a mitochondrial-derived peptide, it is a synthetic peptide designed to interact with the inner mitochondrial membrane.
A 2025 review in the International Journal of Molecular Sciences examined Elamipretide's structure, mechanism of action, and therapeutic potential in detail. Key mechanistic features:
Unlike Humanin and MOTS-c (which remain primarily research compounds), Elamipretide has undergone substantial clinical development:
The Elamipretide clinical experience illustrates both the promise and difficulty of mitochondrial-targeted therapeutics — the mechanism is real and well-characterized, but translating mitochondrial improvements into clinically meaningful endpoints has been challenging.
The collective body of research on mitochondrial-derived peptides represents a relatively new scientific field with several distinctive features:
Mechanistic novelty. Mitochondrial-derived peptides represent a genuinely new class of signaling molecules with mechanisms distinct from classical hormone or growth factor biology.
Aging biology relevance. Multiple mitochondrial peptides show declining expression with age and effects on age-related pathologies, positioning the field as central to longevity research.
Limited clinical translation. Despite mechanistic interest, the field has not yet produced approved clinical therapies, with Elamipretide representing the most advanced but still incomplete clinical development.
Research peptide use. Both Humanin and MOTS-c are widely available for research use, with growing application in preclinical models of aging, neurodegeneration, and metabolic disease.
For research interpretation across the three compounds:
Humanin — Mechanism is well-characterized, neuroprotective effects are reproducible in preclinical models, lifespan effects in animal models are documented, cancer-related concerns require careful consideration in any clinical translation, and human clinical efficacy data is limited.
MOTS-c — Metabolic effects are mechanistically supported and reproducibly documented, muscle health applications represent the most promising clinical direction, aging-related declines support biomarker research, and clinical trials are in early phases.
Elamipretide — Mitochondrial mechanism is well-validated, clinical development is substantial but incomplete, no approved indication exists as of this writing, and ongoing trials continue to refine the clinical role.
The mitochondrial peptide field represents one of the more genuinely novel areas of modern peptide research, with implications for aging biology, metabolic disease, neurodegeneration, and cellular bioenergetics. Whether it produces clinically transformative therapies in the next decade will depend on how well the mechanistic novelty translates to clinical endpoint improvements.
NoteThis article is intended for informational and educational purposes only. It does not constitute medical advice.
Still have questions?
ASK AXIOM ABOUT THIS TOPIC →